Benlysta May Lead Wave Of New Approvals For Lupus Drugs
This article was originally published in Start Up
Executive Summary
The looming approval of Benlysta may create an easier pathway to approval for other lupus candidates, while leaving a potentially broad opportunity for other drugs to fill gaps in its label. Start-Up profiles three emerging lupus drug developers: Azano Pharmaceuticals, Resolve Therapeutics and SuppreMol